FOURKITES
5.3.2024 13:31:28 CET | Business Wire | Press release
Barilla, the world leader in pasta production, has announced that it has achieved 80% visibility into the entire lifecycle of its ocean and road shipments, thanks to leading supply chain visibility provider FourKites. The end-to-end transparency offered by FourKites® allows Barilla to see exactly where its goods are anywhere in the supply chain, as well as when they’ll arrive at their final destination. In the face of military conflict in the Red Sea, disruptive weather events and supply shortages, this comprehensive visibility is critical for Barilla to achieve a resilient supply chain that ensures products get to customers in the most efficient way and with the best service.
Barilla has an intricate logistics operation that includes 30 production sites, 15 of which are in Italy and 15 abroad. Each week, the company moves more than 2,000 loads from Italy to over 120 countries via road and ocean shipments.
Armed with FourKites’ highly accurate, AI-enabled predictive estimated times of arrival (ETAs), Barilla’s customers can confidently plan their operations around scheduled deliveries. Not only are these ETAs updated in transit, but FourKites highlights incorrect planned transit times to ensure that shipments start — and stay — on schedule.
“Before we started using FourKites’ platform, we could only react to an issue when it was too late,” says Davide Busato, Logistic Competence Centre Innovation Project Manager at Barilla. “Now, we react before an issue escalates into a major problem, which saves time while reducing transportation costs and fines. This, in turn, improves our relationships with carriers and customers.”
Ocean shipments are an important part of Barilla’s logistics operation and equal about 10% of its market. Barilla started its collaboration with FourKites by using the company’s over-the-road (OTR) visibility and then expanded coverage to include visibility into all its ocean shipments.
“Freight forwarders had overseen Barilla’s ocean shipments, but it was costly and time-consuming because we had to manually check with carriers on the location of shipments,” continues Busato. “Adding FourKites’ ocean visibility to our setup was an obvious choice, and it’s paid off handsomely. Now, we don’t need to spend time hunting for answers and instead can focus on more important tasks like acting on the FourKites data to improve customer satisfaction.”
“With supply chains under enormous pressure due the conflict in the Red Sea and the drought in the Panama Canal, the need for highly accurate supply chain insights is imperative,” says Marc Boileau, Senior Vice President FourKites EMEA. “We’re delighted Barilla is using FourKites to identify exceptions early, so they can take action and prioritize work based on impact. We look forward to continuing our partnership with them.”
“Our goals with FourKites in 2024 are to track 90% of our shipments, reduce penalties with carriers by 5% and decrease inefficient communication with partners by 10-15%. We’re currently well on our way to meeting these metrics,” Busato says.
FourKites recently announced several enhancements to its next-generation ocean visibility platform, Dynamic Ocean®. By providing better context, clarity and control throughout every ocean shipment, these new features help FourKites users mitigate global disruptions; reduce costly fees like preventable detention and demurrage charges; and exceed customer expectations.
About FourKites
Leading global supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3.2 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
About Barilla
The Barilla Group Barilla is a family business, not listed on the Stock Exchange, chaired by the brothers Guido, Luca and Paolo Barilla. It was founded by their great-grandfather Pietro Barilla, who opened a bakery in Parma in 1877. Today, Barilla is renowned in Italy and around the world for the excellence of its food products. With its brands – Barilla, Mulino Bianco, Pan di Stelle, Gran Cereale, Harrys, Pavesi, Wasa, Filiz, Yemina and Vesta, Misko, Voiello, Academia Barilla, First, Catelli, Lancia, Splendor, Tolerant, Pasta Evangelists and Back to Nature – it advocates tasty, hearty and wholesome nutrition, inspired by the Mediterranean Diet and the Italian lifestyle. When Pietro opened his shop 146 years ago, the main aim was to make good food. That principle has now become the Barilla way of doing business, with more than 8,700 people working for the company and a supply chain that shares its values and passion for quality. The Group's commitment is to offer people the joy that good, well-made food can bring them, produced with selected ingredients from responsible supply chains, to contribute to a better present and future. Since 1987, a historical archive has been collecting and preserving the company’s 146-year history, now a resource open to all via the portal-museum www.archiviostoricobarilla.com, a testament to the journey of an icon among Made in Italy products and to the changes in Italian society. For further info, visit: www.barillagroup.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305317743/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
